## J.P.Morgan

## PetroChina - H

Upstream profitability sustainable; natural gas import/chemical losses to narrow; pipeline restructuring soon

We believe PetroChina's management update is likely to be taken positively by the market, with its focus on cost optimization, restructuring and environmental efficiency. We have been surprised at PetroChina's ability to sustain upstream profitability, and there is clearly "low-hanging fruit" in terms of cost-cutting.

- Positive on upstream profitability: PetroChina indicated continued upstream profitability for the first two months in FY15. Cost-cutting remains a focus (the company targets flat lifting costs) with field managers' salaries linked to profit and squeezing mature fields (e.g., Liaohe/Jilin).
- M&A still on the agenda: With a c16-year proven reserve life and expectations of low oil prices for a long period of time, PetroChina sees good M&A opportunities. The emphasis was on conventional assets, rather than oil sands/CBM, with potential for equity/asset swaps with large firms or M&A with small, cash-strapped companies.
- Plans for restructuring: Pipeline restructuring is extended to the majority of the domestic oil/gas pipeline network (not just west/east parts of the West-East gas pipeline), subject to government approval. The company is looking at marketing reform, with pilot programs in Xinjiang and two Eastern provinces.
- Chemicals recovery: PetroChina expects to reduce its chemicals loss by c30% (implied cRmb12bn loss in FY15) and sees an improving chemicals market.
- Natural gas loss to narrow: PetroChina forecasts an LNG/pipeline import natural gas loss of Rmb15-20bn this year (was Rmb35bn in FY14), which reflects not only pricing impact, but also perhaps lower LNG volumes.
- Minor changes to FY15E/17E EPS; maintain Dec-15 PT and rating.

PetroChina - H (Routers: 0857 HK Ricomberg: 857 HK)

retroclina - n (Reuters, 0057.nk, bloomberg, 657 nk)									
Rmb in mn, year-end Dec	FY12A	FY13A	FY14A	FY15E	FY16E				
Revenue (Rmb mn)	2,195,296	2,258,124	2,282,962	1,368,253	1,552,063				
Net Profit (Rmb mn)	115,326	129,599	107,172	59,589	78,468				
EPS (Rmb)	0.63	0.71	0.59	0.33	0.43				
DPS (Rmb)	0.32	0.32	0.26	0.15	0.19				
Revenue Growth (%)	9.6%	2.9%	1.1%	(40.1%)	13.4%				
EPS Growth (%)	(13.3%)	12.4%	(17.3%)	(44.4%)	31.7%				
ROCE	9.7%	8.4%	7.7%	4.2%	5.0%				
ROE	11.2%	11.8%	9.3%	4.9%	6.2%				
P/E	10.6	9.4	11.4	20.5	15.6				
P/BV	1.2	1.1	1.0	1.0	1.0				
EV/EBITDA	7.8	7.8	7.6	11.1	9.4				
Dividend Yield	4.7%	4.8%	3.9%	2.2%	2.9%				

Source: Company data, Bloomberg, J.P. Morgan estimates.

#### Neutral

**0857.HK**, **857 HK** Price: HK\$8.35

Price Target: HK\$8.20

Hong Kong Integrated Oils

Scott L Darling AC

(852) 2800 8578

scott.darling@jpmorgan.com

Bloomberg JPMA DARLING <GO>

Michael Stansfield

(852) 2800-8563

michael.stansfield@jpmorgan.com

Parsley Rui Hua Ong

(852) 2800-8509

parsley.rh.ong@jpmorgan.com

J.P. Morgan Securities (Asia Pacific) Limited



Company Data	
Shares O/S (mn)	21,099
Total Market Cap(A+H) (HK\$	2,548,917
mn)	
Total Market Cap(A+H) - USD	328,689
(\$ mn)	
Price (HK\$)	8.35
Date Of Price	26 Mar 15
Free Float(%)	98.6%
3M - Avg daily vol (mn)	92.99
3M - Avg daily val (HK\$ mn)	800.27
3M - Avg daily val (\$ mn)	103.2
HSCEI	11,919.69
Exchange Rate	7.75
Price Target End Date	31-Dec-15

See page 7 for analyst certification and important disclosures, including non-US analyst disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Key catalysts for the stock price:

1) 1Q earnings announcement (watch for refining/chemicals improvement and upstream profitability)

2) Pipeline/marketing restructuring

Upside risks to our view:

A sharp increase in crude oil prices, driving E&P profits

Downside risks to our view:

A sharp fall in oil prices, recent natural gas price hikes not being passed through to customers and any further rises, a higher import burden and weak chemicals profitability from lower demand and margins

Key financial metrics	FY14	FY15E	FY16E	FY17E
Revenues (LC)	2,282,962	1,368,253	1,552,063	1,751,615
Revenue growth (%)	1%	(40%)	13%	13%
EBITDA (LC)	347,296	252,269	305,746	349,062
EBITDA margin (%)	15%	18%	20%	20%
Tax rate (%)	24%	22%	22%	22%
Net profit (LC)	107,172	59,589	78,468	81,778
EPS (LC)	0.586	0.326	0.429	0.447
EPS growth (%)	(17%)	(44%)	32%	4%
DPS (LC)	0.264	0.147	0.193	0.201
Operating cash flow (LC mn)	335,056	147,034	228,203	255,908
Free cash flow (LC mn)	59,821	(99,484)	6,490	47,624
Interest cover (X)	16.0	10.2	11.1	12.2
Net margin (%)	5%	4%	5%	5%
Sales/assets (X)	1.0	0.6	0.6	0.7
Debt/equity (%)	41%	47%	51%	53%
Net debt/equity (%)	35%	44%	48%	48%
ROE (%)	9%	5%	6%	6%
Key model assumptions	FY14	FY15E	FY16E	FY17E
Oil price assumption	99	49	57	65
Total oil and gas production (000 boe/d)	3,835	3,973	4,015	4,088

Source: Bloomberg, Company and J.P. Morgan estimates.


Sensitivity analysis	EBITDA		EPS	
Sensitivity to	FY15E	FY16E	FY15E	FY16E
Impact of each +US\$5/bbl	5%	5%	5%	5%

Source: Bloomberg, Company and J.P. Morgan estimates.

#### Valuation and price target basis

Our Dec-15 PT for PetroChina-H of HK\$8.20 is based on a sumof-the-parts methodology, whereby we calculate a DCF-based value for each business segment. Debt and financial liabilities are deducted at book value.

Price target breakdown - PetroChina-H



Source: Bloomberg, Company and J.P. Morgan estimates.

JPMe vs. consensus, change in estimates					
EPS	FY15E	FY16E			
JPMe old	0.288	0.443			
JPMe new	0.326	0.429			
% chg	13%	(3%)			
Consensus	0.294	0.509			

Source: Bloomberg, Company and J.P. Morgan estimates.

Asia Oil & Gas coverage comparative metrics

			CMP	Pot. upside	Market	P/E (x	)	P/B (x		EV/EBITD	A (x)	YTD
Company name	Rating	PT (LC)	(LC)	to PT (%)	cap (\$ B)	15Y	16Y	15Y	16Y	15Y	16Y	perf (%)
PETROCHINA-H	N	8.20	8.35	(1.8)	335.3	20.5	15.6	1.0	1.0	11.1	9.4	(2.9)
SINOPEC CORP-H	N	5.70	6.05	(5.8)	119.0	21.1	13.8	0.9	0.9	8.3	7.1	(3.2)
CNOOC	UW	9.00	10.56	(14.8)	60.8	19.7	11.9	1.2	1.3	5.0	4.1	1.1
SINOPEC SHANG-H	UW	1.50	2.68	(44.0)	7.7	30.7	17.9	1.2	1.2	14.6	13.9	18.1
CHINA OILFIELD-H	UW	10.60	12.32	(14.0)	13.8	12.7	11.9	1.0	1.0	11.7	11.0	(8.5)
INPEX CORP	OW	1,560	1,375	13.5	16.9	23.1	18.8	8.0	0.7	5.3	4.1	2.2
OIL & NATURAL GA	UW	300	302	(0.5)	41.0	12.2	9.6	1.3	1.2	5.9	4.7	(12.3)
CAIRN INDIA	N	235	223	5.4	6.6	5.6	11.1	0.7	0.6	2.7	4.5	(6.7)
PTT PCL	N	330	326	1.2	28.6	11.7	10.7	1.2	1.2	6.0	5.9	0.6
PTT EXPL & PROD	UW	95	112	(14.8)	13.6	17.6	17.5	1.0	1.0	3.8	4.1	(0.4)
PETROCHINA CO-A	UW	6.50	11.99	(45.8)	335.3	36.1	27.4	1.7	1.7	11.1	9.4	10.9
CHINA PETROLEU-A	UW	4.60	6.44	(25.5)	119.0	28.0	18.4	1.2	1.1	8.3	7.1	(8.0)
SINOPEC SHANG-A	UW	1.20	5.55	(78.4)	7.7	79.3	46.3	3.1	3.0	14.6	13.9	28.2
CHINA OILFIELD-A	UW	8.50	22.86	(62.8)	13.8	29.3	27.5	2.3	2.2	11.7	11.0	10.1

Source: Company, Bloomberg, J.P. Morgan estimates.

## Cost control and restructuring focus

PetroChina's FY14 analyst briefing highlighted the company's strategy to accelerate further cost optimization (already undertaken in the wake of the management

changes from late 2013). There was more emphasis on energy and environmental efficiency, providing details on coal, water and emissions saved, and an acknowledgement that oil prices will remain low for a long period and that Chinese oil/gas demand growth continues to slow down. Key points:

- **FY15 production targets as expected:** Guidance for oil production growth is down c2% y/y, while natural gas is up 6%, broadly in line with our expectations. RRR >0.7 based on US\$70/bl.
- Natural gas pricing adjustment: PetroChina expect the NDRC's recent announcement to adjust natural gas prices (see note) to "exert some negative impact on the business," but to be a benefit in the long run as the country moves toward market-based pricing.
- **Impairment risks remain:** PetroChina sees no large impairment of upstream assets in the current oil price environment.
- Import gas losses to narrow: PetroChina's forecast of an LNG/pipeline import natural gas loss of Rmb15-20bn this year (was Rmb35bn in FY14) not only reflects a pricing impact (natural gas import prices lag oil prices by around nine months), but also perhaps lower LNG volumes (LNG imports may be <6bcm in FY15 vs. 7.3bcm in FY14).
- Upstream performance linked to pay: The company seems to have linked operational/profitability performance within its upstream to production manager salaries. The company also attributes its upstream performance to efforts made to enhance oil recovery at mature fields (e.g., Liaohe/Jilin), as well as a decrease in administration expenses, transportation and marketing cost.
- Pipeline/marketing restructuring: PetroChina reiterated the government's view that the market should play a decisive role in resource allocation in China. Further optimization of its pipeline assets will be extended to the majority of the gas and oil pipeline portfolio (not just the eastern/western part of West East Pipeline network). However, the company stated that any restructuring must comply with the government and at an acceptable return. A marketing pilot program has been initiated at Xianjiang and two provinces in eastern China. Both West and East models will be evaluated to see which offers the best potential; presumably, this relates to which areas present the best non-fuels growth.
- Positive on chemicals recovery: While the company guided to a slight increase in chemical capex, which relates to projects starting up later this year, capex will be reduced in the long term. Surprisingly, PetroChina is seeing a seasonal pickup in domestic chemicals demand (e.g., fertilizer), with tightening supply as refineries undergo planned maintenance, limiting chemical supply, "coal-to-chemicals competitive edge weakening" in current oil prices, chemicals losses are likely to decline into 2Q15. The company shut down 30 uneconomical units last year and plans to make more efforts to reduce losses (guides to a 30% loss reduction in FY15).



# Adjusting FY15E/17E EPS by an average 1%; maintain PT and ratings

We have adjusted our FY15/17 EPS forecasts by an average of 1% to reflect higher-than-expected refining profitability and weaker-than-expected chemicals profitability.

We maintain our Neutral view and Dec-15 PT for PetroChina-H of HK\$8.20, based on DCF for the different segments, with a WACC of 10.5%.

**Table 1: Sinopec EPS estimate revisions** 

Rmb	New	Old	Consensus	Change	Vs. consensus
15Y	0.33	0.29	0.29	13%	11%
16Y	0.43	0.44	0.51	(3%)	(16%)
17Y	0.45	0.48	0.84	(7%)	(47%)

Source: J.P. Morgan estimates. % change refers to new estimates.

## Investment Thesis, Valuation and Risks

#### PetroChina - H (Neutral; Price Target: HK\$8.20)

#### **Investment Thesis**

PetroChina is the largest oil company in China and one of the largest globally. It is integrated with E&P, R&C, marketing and pipelines (NGP). In 2014, crude production was 2.6mn BOPD and natural gas 1.5mn BOPD, refining throughput 2.75mn BOPD and chemical production 21.5mn tonnes, and it operated over 40,000km of pipelines (crude, products and natural gas). PetroChina has proven reserves of 23.4bn BOE (55% natural gas, 68% of crude is developed). Major profit drivers are crude prices and refining margins in China. Our Neutral view of PetroChina-H is based on:

- Shift in energy portfolio to be rewarded We expect investor focus to be on
  the company's ability to strategically shift its energy portfolio away from lowreturn assets via asset divestments. We think visibility on asset divestments will
  lead to outperformance relative to local peers.
- Headwinds from global oil market; downstream drag on earnings With crude oil markets pressured, we believe the upstream-focused PetroChina will be in a period of lackluster returns; additionally, the downstream segment looks to be a continued burden (1Q15 theoretical China GRMs beginning in negative territory; chemicals look on track to continue to be a loss-making business).

#### Valuation

Our Dec-15 PT of HK\$8.20 is based on a sum-of-the-parts methodology, whereby we calculate a DCF-based value (WACC 10.5%, terminal g 2%) for each business segment (upstream, refining, chemicals and marketing) to give our total NAV. Debt and financial liabilities are deducted at book value.

#### Risks to Rating and Price Target

Downside risks to our rating and price target include a sharp fall in oil prices, recent natural gas price hikes not being passed through to customers and no further rises, a higher import burden and weak chemicals profitability from lower demand and margins. Upside risks include a sharp increase in crude oil prices, driving E&P profits.

## PetroChina - H: Summary of Financials

Remb in millions, year end Dec		••••	<u> </u>	. w. y	<u> </u>	14110						
Revenues	Income Statement											
% change Y/Y         2.9%         1.1%         (40.1%)         13.4%         12.9%         Dept. A amortization         163.365         177.463         154.820         100.202         22.138         2.1%         6.2%         252.269         305.746         349.062         Change in working capital         20.30         25.491         (87.098)         (53.819)         (68.519)         (85.191)         (85.819)         (85.819)         (85.819)         (85.819)         (85.819)         (85.819)         (85.819)         (85.819)         (82.723)         248.355         24.905         22.9703         Cash flow from operations         327.938         335.056         147.034         228.203         256.908           BEIT Margin         7.5%         7.4%         7.1%         8.0%         7.4%         Capex         (318.074)         (291.729)         (266.000)         (243.290)         (230.90)         (20.859)         (21.723)         (24.817)         (27.887)         (28.670)         Disposal/(purchase)	Rmb in millions, year end Dec	FY13	FY14	FY15E	FY16E	FY17E	Rmb in millions, year end Dec	FY13	FY14	FY15E	FY16E	FY17E
EBITDA 3 33,147 347,296 252,269 305,746 349,062 Change in working capital (20,300 25,491 (87,098) (63,819) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,519) (85,319) (85,	Revenues	2,258,124	2,282,962	1,368,253	1,552,063	1,751,615	EBIT	169,782	169,833	97,449	124,925	129,703
% change YYY         2.0%         4.2%         (27.4%)         21.2%         14.2%         Taxes         (35.789)         (37.73)         (18.138)         (23.723)         24.635           BT         (69.782)         169,833         97.449         124,925         129,703         Cash flow from operations         327.93         335,056         147,034         228,203         255,908           Well Addragin         7.5%         7.4%         7.1%         8.0%         7.4%         Cash flow from operations         33.80         147,034         221,203         225,509         255,009         255,000         255,000         255,000         20,000         26,000         (21,329)         (23,079)         255,000         20,000<	% change Y/Y	2.9%	1.1%	(40.1%)	13.4%	12.9%	Depr. & amortization	163,365	177,463	154,820	180,820	219,359
EBIT 169,782 169,833 97,449 124,925 329,703 Cash flow from operations 327,938 335,056 147,034 228,203 255,908   % change YYY (2,7%) 0.0% (42,6%) 28,2% 3.8%   **Relit Margin 7.5% 7.4% 7.4% 7.1% 8.0% 7.4% (26,60) Classes (20,859) (21,723) (243,270) (230,750)   Net Interest (20,859) (21,723) (24,817) (27,487) (28,670) Disposal/(purchase)   **Earlings before tax (159,203 156,759 84,361 110,341 114,580 Net Interest (20,859) (21,723) (24,817) (27,487) (28,670)   % change YYY (4,6%) (1,5%) (46,2%) 30,8% 3.8% Other incress (20,859) (21,723) (24,817) (27,487) (28,670)   Tax (35,769) (37,731) (18,138) (23,723) (24,635) Free cash flow   **Change YYY (12,4%) (15,5%) (46,2%) 30,8% 3.8% Other incress (20,859) (21,723) (24,817) (27,487) (28,670)   **Change YYY (12,5%) (44,4%) 31,7% 4.2% Other 33,510 (78,881) 103,963 50,763 (11,444)   EPS (reported) (12,599) 107,172 59,589 78,468 81,778   **Change YYY (12,4%) (17,3%) (44,4%) 31,7% 4.2% Other 33,510 (78,881) 103,963 50,763 (11,444)   EPS (reported) (17,3%) (44,4%) 31,7% 4.2% Other 33,510 (78,881) 103,963 50,763 (11,444)   EPS (reported) (17,3%) (44,4%) 31,7% 4.2%   Beginning cash (34,395 51,407 73,778 25,175 38,443   Cash and cash equivalents 51,407 73,778 25,175 38,443   Cash and cash equivalents 78,387 65,931 41,490 54,124 70,245 EBIT margin 7,5% 7,4% 7,4% 1,1% 19,7%   Cash and cash equivalents 74,122 85,652 69,183 85,769 105,94    ET investments 74,122 85,652 69,183 89,128   ET investments 192,767 169,178 91,188,778 1,95,748 1,95,769 N   EVER YEAR STAN STAN STAN STAN STAN STAN STAN STAN	EBITDA	333,147	347,296	252,269	305,746	349,062	Change in working capital	20,300	25,491	(87,098)	(53,819)	(68,519)
% change YYY         (2,7%)         0.0%         42,6% % of 2,2% with 1 (2,0%)         28.2% of 2,4% with 1 (2,0%)         3.3% with 1 (2,0%)         Capex         (318,074) (291,729) (266,000) (243,290) (230,790)         (20,0%) (243,290) (243,290) (230,790)         (20,0%) (243,290) (230,790)         (20,0%) (243,290) (230,790)         (20,0%) (243,290) (230,790)         (20,0%) (243,290) (243,290) (243,290) (240,290) (243,290) (240,290)         (20,0%) (243,290) (230,290) (243,290) (240,290) (243,290) (243,290) (240,290) (240,290)         (20,0%) (24,0%) (240,290	% change Y/Y	2.0%	4.2%	(27.4%)	21.2%	14.2%	Taxes	(35,789)	(37,731)	(18, 138)	(23,723)	(24,635)
EBIT Margin	EBIT	169,782	169,833	97,449	124,925	129,703	Cash flow from operations	327,938	335,056	147,034	228,203	255,908
Net Interest (20,859) (21,723) (24,817) (27,487) (28,670) Disposal/(purchase) (20,859) (21,723) (24,817) (27,487) (28,670) Net Interest (28,670) Net Interest (28,670) (28,578) (21,57	% change Y/Y	(2.7%)	0.0%	(42.6%)	28.2%	3.8%						
Earning's before tax	EBIT Margin	7.5%	7.4%	7.1%	8.0%	7.4%	Capex	(318,074)	(291,729)	(266,000)	(243,290)	(230,790)
% change Y/Y         (4.6%)         (1.5%)         (46.2%)         30.8%         3.8%         Other         51,564         891         0         0         0           Tax         (35,789)         (37,731)         (18,138)         (23,723)         (24,635)         Free cash flow         26,034         59,821         (99,484)         6,490         47,624           as % of EBT         22,5%         24,1%         21,5%         42,0%         20,1%         21,5%         42,0%         21,1%         21,1%         42,0%         21,1%         42,0%         21,1%         42,0%         20,1%         21,1%         42,0%         21,1%         42,0%         21,1%         21,14         42,0%         21,14         42,0%         21,14         42,0%         21,14         42,0%         21,14         42,0%         21,14         42,0%         21,14         41,14 <td< td=""><td>Net Interest</td><td>(20,859)</td><td>(21,723)</td><td>(24,817)</td><td>(27,487)</td><td>(28,670)</td><td>Disposal/(purchase)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></td<>	Net Interest	(20,859)	(21,723)	(24,817)	(27,487)	(28,670)	Disposal/(purchase)	-	-	-	-	-
Tax (35,789) (37,731) (18,138) (23,723) (24,63) Free cash flow 26,034 59,821 (99,484) 6,490 47,624 as % of EBT 22,599 17,172 59,589 78,486 81,778 Equity raised/(repaid) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Earnings before tax	159,203	156,759	84,361	110,341	114,580	Net Interest	(20,859)	(21,723)	(24,817)	(27,487)	(28,670)
Second Control   Seco	% change Y/Y	(4.6%)	(1.5%)	(46.2%)	30.8%	3.8%	Other	51,564	891	0	0	0
Net income (reported) % change Y/Y 12.4% 17.3% 183,021 184,033 184,04 184,043	Tax	(35,789)	(37,731)	(18,138)	(23,723)	(24,635)	Free cash flow	26,034	59,821	(99,484)	6,490	47,624
Sk change Y/Y         12.4%         (17.3%)         (44.4%)         31.7%         4.2%         Debt raised/(repaid)         12.571         82.796         (18.515)         0         35.176         (14.44)           Shares outstanding         183.021         0.43         0.45         0.05         0.05         0.52         105.6800         103.0800	as % of EBT	22.5%	24.1%	21.5%	21.5%	21.5%				, ,		
Sk change Y/Y         12.4%         (17.3%)         (44.4%)         31.7%         4.2%         Debt raised/(repaid)         12.571         82.796         (18.515)         0         35.176         24.444         33.510         (78.881)         103.963         50.763         (11.444)           PSPS (reported)         0.71         0.59         0.33         0.43         0.45         bividends paid         (88.320)         (82.27)         (26.815)         (35.10)         (36.800)         (36.800)         (36.800)         (36.800)         (36.800)         (36.800)         (30.20)         0.02         0.05         51.407         73,778         25.175         38.443         64.043         PS         PS         0.32         0.02         0.15         73,778         25.175         38.443         64.043         PS         PS         0.32         0.02         0.15         73,778         25.175         38.443         64.043         PS         PS         0.032         0.02         0.15         73,778         25.175         38.443         64.043         PS         PS         1.18         PS         PS         1.18         PS         PS         PS         PS         PS         PS         1.18         PS         PS         PS	Net income (reported)	129,599	107,172	59,589	78,468	81,778	Equity raised/(repaid)	0	0	0	0	0
EPS (reported)	% change Y/Y	12.4%		(44.4%)	31.7%	4.2%	Debt raised/(repaid)	12,571	82,796	(18,515)	0	35,179
We change YIY   12.4%   (17.3%)   (44.4%)   31.7%   4.2%   Beginning cash   43.395   51,407   73,778   25,175   38,443   64,043   DPS   0.32   0.26   0.15   0.19   0.20	Shares outstanding	183,021	183,021	183,021	183,021	183,021	Other	33,510	(78,881)	103,963	50,763	(11,444)
Ending cash   DPS   DP	EPS (reported)	0.71	0.59	0.33	0.43	0.45	Dividends paid	(58,320)	(48,227)	(26,815)	(35,310)	(36,800)
Ending cash   DPS   DP	% change Y/Y	12.4%	(17.3%)	(44.4%)	31.7%	4.2%	Beginning cash	43,395	51,407	73,778	25,175	38,443
Part	ŭ		,	,			Ending cash	51,407	73,778	25,175	38,443	64,043
Rmb in millions, year end Dec   FY13   FY14   FY15E   FY16E   FY17E   Rmb in millions, year end Dec   FY13   FY14   FY15E   FY16E   FY17E   Rmb in millions, year end Dec   FY13   FY14   FY15E   FY16E   FY17E   Rmb in millions, year end Dec   FY13   FY14   FY15E   FY16E   FY17E   FY16E   FY17E   Rmb in millions, year end Dec   FY13   FY14   FY15E   FY16E   FY17E   FY16E												
Cash and cash equivalents	Balance sheet						Ratio Analysis					
Cash and cash equivalents	Rmb in millions, year end Dec	FY13	FY14	FY15E	FY16E	FY17E	Rmb in millions, year end Dec	FY13	FY14	FY15E	FY16E	FY17E
Net margin   10   10   10   10   10   10   10   1	Cash and cash equivalents	51,407	73,778	25,175	38,443	64,043		14.8%	15.2%	18.4%	19.7%	19.9%
Net margin   10   10   10   10   10   10   10   1	Accounts receivable	78.387	65.931	41,490	54.124	70.245	EBIT margin	7.5%	7.4%	7.1%	8.0%	7.4%
Others 74,142 85,622 69,183 85,769 105,934 Current assets 430,953 391,308 240,297 311,034 407,953 Sales per share growth 2.9% 1.1% (40.1%) 13.4% 12.9%	Inventories			,	,					4.4%		4.7%
Current assets 430,953 391,308 240,297 311,034 407,953 Sales per share growth 2.9% 1.1% (40.1%) 13.4% 12.9% Net fixed assets 1,648,823 1,747,691 1,898,778 1,953,748 1,957,679 Net profit growth 12.4% (17.3%) (44.4%) 31.7% 4.2% Total Assets 2,342,110 2,405,473 2,407,169 2,535,091 2,640,117 EPS growth 12.4% (17.3%) (44.4%) 31.7% 4.2% Liabilities Interest coverage (x) 16.0 16.0 10.2 11.1 12.2 Short-term loans 192,767 169,128 299,128 379,128 399,128 Payables 383,004 364,060 174,554 178,203 181,004 Net debt to equity 34.3% 34.9% 44.4% 47.7% 48.1% Others 69,718 46,641 46,641 46,641 46,641 Sales/assets 1.0 1.0 0.6 0.6 0.7 Total current liabilities 645,489 579,829 520,323 603,972 626,773 Assets/equity 2.1 2.1 2.0 2.0 2.0 10.0 Charm debt 302,862 370,301 351,786 351,786 386,965 ROE 11.8% 9.3% 4.9% 6.2% 6.3% Other liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299 Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	Others				,		3					
Sales per share growth 2.9% 1.1% (40.1%) 13.4% 12.9%   LT investments Sales growth 2.9% 1.1% (40.1%) 13.4% 12.9%   Net fixed assets 1,648,823 1,747,691 1,898,778 1,953,748 1,957,679   Net profit growth 12.4% (17.3%) (44.4%) 31.7% 4.2%   Total Assets 2,342,110 2,405,473 2,407,169 2,535,091 2,640,117   EPS growth 12.4% (17.3%) (44.4%) 31.7% 4.2%   Interest coverage (x) 16.0 16.0 10.2 11.1 12.2   Short-term loans 192,767 169,128 299,128 379,128 399,128   Payables 383,004 364,060 174,554 178,203 181,004   Net debt to equity 34.3% 34.9% 44.4% 47.7% 48.1%   Others 69,718 46,641 46,641 46,641 46,641 Sales/assets 1.0 1.0 0.6 0.6 0.7   Total current liabilities 645,489 579,829 520,323 603,972 626,773   Assets/equity 2.1 2.1 2.0 2.0 2.0   Long-term debt 302,862 370,301 351,786 351,786 386,965   Other liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299   Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	Current assets	430.953	391.308	240.297	311.034	407.953						
LT investments		,	,	-, -	,	,	Sales per share growth	2.9%	1.1%	(40.1%)	13.4%	12.9%
Net fixed assets 1,648,823 1,747,691 1,898,778 1,953,748 1,957,679 Net profit growth 12.4% (17.3%) (44.4%) 31.7% 4.2% Total Assets 2,342,110 2,405,473 2,407,169 2,535,091 2,640,117 EPS growth 12.4% (17.3%) (44.4%) 31.7% 4.2% Interest coverage (x) 16.0 16.0 10.2 11.1 12.2 Short-term loans 192,767 169,128 299,128 379,128 399,128 Payables 383,004 364,060 174,554 178,203 181,004 Net debt to equity 34.3% 34.9% 44.4% 47.7% 48.1% Others 69,718 46,641 46,641 46,641 46,641 46,641 Sales/assets 1.0 1.0 0.6 0.6 0.7 Total current liabilities 645,489 579,829 520,323 603,972 626,773 Assets/equity 2.1 2.1 2.0 2.0 2.0 Long-term debt 302,862 370,301 351,786 351,786 386,965 ROE 11.8% 9.3% 4.9% 6.2% 6.3% Other liabilities 123,824 137,562 137,562 137,562 137,562 137,562 ROCE 8.4% 7.7% 4.2% 5.0% 4.9% Total Liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299 Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	LT investments	-	-	_	-	-	, ,			,		
Total Assets 2,342,110 2,405,473 2,407,169 2,535,091 2,640,117 EPS growth 12.4% (17.3%) (44.4%) 31.7% 4.2% Interest coverage (x) 16.0 16.0 10.2 11.1 12.2   Short-term loans 192,767 169,128 299,128 379,128 399,128   Payables 383,004 364,060 174,554 178,203 181,004 Net debt to equity 34.3% 34.9% 44.4% 47.7% 48.1% Others 69,718 46,641 46,641 46,641 46,641 Sales/assets 1.0 1.0 0.6 0.6 0.7   Total current liabilities 645,489 579,829 520,323 603,972 626,773 Assets/equity 2.1 2.1 2.0 2.0 2.0   Long-term debt 302,862 370,301 351,786 351,786 386,965 ROE 11.8% 9.3% 4.9% 6.2% 6.3% Other liabilities 123,824 137,562 137,562 137,562 137,562 137,562 ROCE 8.4% 7.7% 4.2% 5.0% 4.9% Total Liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299   Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	Net fixed assets	1.648.823	1.747.691	1.898.778	1.953.748	1.957.679	•			,		
Liabilities   Interest coverage (x)   16.0   16.0   10.2   11.1   12.2   Short-term loans   192,767   169,128   299,128   379,128   399,128   Payables   383,004   364,060   174,554   178,203   181,004   Net debt to equity   34.3%   34.9%   44.4%   47.7%   48.1%   Others   69,718   46,641   46,641   46,641   46,641   Sales/assets   1.0   1.0   0.6   0.6   0.7   Total current liabilities   645,489   579,829   520,323   603,972   626,773   Assets/equity   2.1   2.1   2.0   2.0   2.0   Long-term debt   302,862   370,301   351,786   351,786   386,965   ROE   11.8%   9.3%   4.9%   6.2%   6.3%   Other liabilities   123,824   137,562   137,562   137,562   137,562   ROCE   8.4%   7.7%   4.2%   5.0%   4.9%   Total Liabilities   1,072,175   1,087,692   1,009,671   1,093,320   1,151,299   Shareholder's equity   1,132,735   1,175,894   1,248,976   1,285,099   1,323,979	Total Assets						1 0		,	,	31.7%	4.2%
Short-term loans         192,767         169,128         299,128         379,128         399,128           Payables         383,004         364,060         174,554         178,203         181,004         Net debt to equity         34.3%         34.9%         44.4%         47.7%         48.1%           Others         69,718         46,641         46,641         46,641         46,641         8.28e/assets         1.0         1.0         0.6         0.6         0.7           Total current liabilities         645,489         579,829         520,323         603,972         626,773         Assets/equity         2.1         2.1         2.0         2.0         2.0           Long-term debt         302,862         370,301         351,786         351,786         386,965         ROE         11.8%         9.3%         4.9%         6.2%         6.3%           Other liabilities         123,824         137,562         137,562         137,562         ROCE         8.4%         7.7%         4.2%         5.0%         4.9%           Total Liabilities         1,072,175         1,087,692         1,090,671         1,093,320         1,151,299         1,132,735         1,175,894         1,248,976         1,285,099         1,323,379         4.9%	Liabilities	,- , -	,, -	, - ,	,,	,,	·		,	,		
Payables 383,004 364,060 174,554 178,203 181,004 Net debt to equity 34.3% 34.9% 44.4% 47.7% 48.1% Others 69,718 46,641 46,641 46,641 46,641 Sales/assets 1.0 1.0 0.6 0.6 0.7 Total current liabilities 645,489 579,829 520,323 603,972 626,773 Assets/equity 2.1 2.1 2.0 2.0 2.0 Long-term debt 302,862 370,301 351,786 351,786 386,965 ROE 11.8% 9.3% 4.9% 6.2% 6.3% Other liabilities 123,824 137,562 137,562 137,562 137,562 ROCE 8.4% 7.7% 4.2% 5.0% 4.9% Total Liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299 Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979		192 767	169 128	299 128	379 128	399 128	interest severage (x)	10.0	10.0	10.2		12.2
Others       69,718       46,641       46,641       46,641       46,641       46,641       46,641       5ales/assets       1.0       1.0       0.6       0.6       0.7         Total current liabilities       645,489       579,829       520,323       603,972       626,773       Assets/equity       2.1       2.1       2.0       2.0       2.0         Long-term debt       302,862       370,301       351,786       351,786       386,965       ROE       11.8%       9.3%       4.9%       6.2%       6.3%         Other liabilities       123,824       137,562       137,562       137,562       ROCE       8.4%       7.7%       4.2%       5.0%       4.9%         Total Liabilities       1,072,175       1,087,692       1,009,671       1,093,320       1,151,299         Shareholder's equity       1,132,735       1,175,894       1,248,976       1,285,099       1,323,979			,		,	,	Net debt to equity	34.3%	34 9%	44 4%	47 7%	48 1%
Total current liabilities 645,489 579,829 520,323 603,972 626,773 Assets/equity 2.1 2.1 2.0 2.0 2.0 2.0 Long-term debt 302,862 370,301 351,786 351,786 386,965 ROE 11.8% 9.3% 4.9% 6.2% 6.3% Other liabilities 123,824 137,562 137,562 137,562 137,562 ROCE 8.4% 7.7% 4.2% 5.0% 4.9% Total Liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299 Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	•				,		1 7					
Long-term debt       302,862       370,301       351,786       351,786       386,965       ROE       11.8%       9.3%       4.9%       6.2%       6.3%         Other liabilities       123,824       137,562       137,562       137,562       ROCE       8.4%       7.7%       4.2%       5.0%       4.9%         Total Liabilities       1,072,175       1,087,692       1,009,671       1,093,320       1,151,299         Shareholder's equity       1,132,735       1,175,894       1,248,976       1,285,099       1,323,979		,	,	,	,	,						
Other liabilities       123,824       137,562       137,562       137,562       ROCE       8.4%       7.7%       4.2%       5.0%       4.9%         Total Liabilities       1,072,175       1,087,692       1,009,671       1,093,320       1,151,299         Shareholder's equity       1,132,735       1,175,894       1,285,099       1,323,979						,	' '					
Total Liabilities 1,072,175 1,087,692 1,009,671 1,093,320 1,151,299 Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979	•	,			,	,						
Shareholder's equity 1,132,735 1,175,894 1,248,976 1,285,099 1,323,979		,			,	,		J. 170	1.1.70	1.2/0	0.070	1.570
3VPS (RMN) N 19 N 42 N 82 / 112 / 23	BVPS (Rmb)	6.19				7.23						

Source: Company reports and J.P. Morgan estimates.


Analyst Certification: The research analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. For all Korea-based research analysts listed on the front cover, they also certify, as per KOFIA requirements, that their analysis was made in good faith and that the views reflect their own opinion, without undue influence or intervention.

#### **Important Disclosures**

- Beneficial Ownership (1% or more): J.P. Morgan beneficially owns 1% or more of a class of common equity securities of PetroChina H.
- Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: PetroChina H.
- Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: PetroChina H.
- Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from PetroChina H.

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan—covered companies by visiting <a href="https://jpmm.com/research/disclosures">https://jpmm.com/research/disclosures</a>, calling 1-800-477-0406, or e-mailing <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a> with your request. J.P. Morgan's Strategy, Technical, and Quantitative Research teams may screen companies not covered by J.P. Morgan. For important disclosures for these companies, please call 1-800-477-0406 or e-mail <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a>.





Date	Rating	Share Price (HK\$)	Price Target (HK\$)
23-Mar-07	OW	8.66	7.40
30-Mar-07	UW	9.27	7.40
01-Aug-07	UW	11.66	8.30
23-Oct-07	UW	19.44	10.20
11-Jan-08	UW	13.68	12.00
19-Mar-08	N	9.60	10.50
19-Apr-08	N	9.82	8.75
06-May-08	UW	12.12	8.75
27-Oct-08	OW	4.25	8.75
08-Jan-09	OW	7.45	8.00
23-Apr-09	UW	6.79	6.00
18-Aug-09	UW	8.50	7.40
17-May-10	UW	8.76	7.60
06-Apr-11	UW	12.22	9.00
08-Nov-11	UW	10.08	8.50
13-May-12	UW	10.44	8.75
31-Oct-12	UW	10.80	8.25
08-May-13	NR	9.97	
02-Jul-13	OW	8.25	11.00
03-Mar-14	OW	8.18	11.25
11-Jul-14	OW	9.80	11.80
28-Aug-14	OW	10.96	12.50
09-Nov-14	OW	9.18	11.50
18-Jan-15	N	8.72	8.20



The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period.

J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

#### Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Not Rated (NR): J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia) and U.K. small- and mid-cap equity research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying analyst's coverage universe can be found on J.P. Morgan's research website, www.jpmorganmarkets.com.

Coverage Universe: Darling, Scott L: Anton Oilfield Services Group (3337.HK), CNOOC (0883.HK), Cairn India Limited (CAIL.BO), China BlueChemical Ltd (3983.HK), China Oilfield Services Limited - H (2883.HK), China Oilfield Services Limited - A (601808.SS), Hilong Holdings Ltd. (1623.HK), Honghua Group (0196.HK), Inpex Corporation (1605) (1605.T), Oil and Natural Gas Corporation (ONGC.BO), PTT Exploration & Production (PTTE.BK), PTT Public Company (PTT.BK), PetroChina - A (601857.SS), PetroChina - H (0857.HK), SPT Energy Group Inc. (1251.HK), Sinopec Corp - A (600028.SS), Sinopec Corp - H (0386.HK), Sinopec Shanghai Petchem - A (600688.SS), Sinopec Shanghai Petchem - H (0338.HK)

#### J.P. Morgan Equity Research Ratings Distribution, as of January 1, 2015

	Overweight	Neutral	Underweight
	(buy)	(hold)	(sell)
J.P. Morgan Global Equity Research Coverage	45%	43%	12%
IB clients*	56%	49%	33%
JPMS Equity Research Coverage	45%	48%	7%
IB clients*	75%	67%	52%

<sup>\*</sup>Percentage of investment banking clients in each rating category.

For purposes only of FINRA/NYSE ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <a href="http://www.jpmorganmarkets.com">http://www.jpmorganmarkets.com</a>, contact the primary analyst or your J.P. Morgan representative, or email <a href="mailto:research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a>.

**Equity Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

**Registration of non-US Analysts:** Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of JPMS, are not registered/qualified as research analysts under NASD/NYSE rules, may not be associated persons of JPMS, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

#### Other Disclosures

J.P. Morgan ("JPM") is the global brand name for J.P. Morgan Securities LLC ("JPMS") and its affiliates worldwide. J.P. Morgan Cazenove is a marketing name for the U.K. investment banking businesses and EMEA cash equities and equity research businesses of JPMorgan Chase & Co. and its subsidiaries.

All research reports made available to clients are simultaneously available on our client website, J.P. Morgan Markets. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your sales representative.

**Options related research:** If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options, please contact your J.P. Morgan Representative or visit the OCC's website at <a href="http://www.optionsclearing.com/publications/risks/riskstoc.pdf">http://www.optionsclearing.com/publications/risks/riskstoc.pdf</a>

#### **Legal Entities Disclosures**

U.S.: JPMS is a member of NYSE, FINRA, SIPC and the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC. U.K.: JPMorgan Chase N.A., London

Branch, is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and to limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from J.P. Morgan on request. J.P. Morgan Securities plc (JPMS plc) is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, Registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. South Africa: J.P. Morgan Equities South Africa Proprietary Limited is a member of the Johannesburg Securities Exchange and is regulated by the Financial Services Board. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong and/or J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. Korea: J.P. Morgan Securities (Far East) Ltd, Seoul Branch, is regulated by the Korea Financial Supervisory Service. Australia: J.P. Morgan Australia Limited (JPMAL) (ABN 52 002 888 011/AFS Licence No: 238188) is regulated by ASIC and J.P. Morgan Securities Australia Limited (JPMSAL) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by ASIC and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. Taiwan: J.P.Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. India: J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai - 400098, is a member of the National Stock Exchange of India Limited (SEBI Registration Number - INB 230675231/INF 230675231/INE 230675231) and Bombay Stock Exchange Limited (SEBI Registration Number - INB 010675237/INF 010675237) and is regulated by Securities and Exchange Board of India. Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: www.jpmipl.com. For non local research reports, this material is not distributed in India by J.P. Morgan India Private Limited. Thailand: This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. Indonesia: PT J.P. Morgan Securities Indonesia is a member of the Indonesia Stock Exchange and is regulated by the OJK a.k.a. BAPEPAM LK. Philippines: J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. Brazil: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. Singapore: This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 199/03/2014 and Co. Reg. No.: 199405335R] which is a member of the Singapore Exchange Securities Trading Limited and is regulated by the Monetary Authority of Singapore (MAS) and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) which is regulated by the MAS. This material is provided in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289. Recipients of this document are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the document. Japan: JPMorgan Securities Japan Co., Ltd. is regulated by the Financial Services Agency in Japan. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission in Malaysia. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan. Saudi Arabia: J.P. Morgan Saudi Arabia Ltd. is authorized by the Capital Market Authority of the Kingdom of Saudi Arabia (CMA) to carry out dealing as an agent, arranging, advising and custody, with respect to securities business under licence number 35-07079 and its registered address is at 8th Floor, Al-Faisaliyah Tower, King Fahad Road, P.O. Box 51907, Riyadh 11553, Kingdom of Saudi Arabia. Dubai: JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - Building 3, Level 7, PO Box 506551, Dubai, UAE.

#### **Country and Region Specific Disclosures**

U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by JPMS plc. Investment research issued by JPMS plc has been prepared in accordance with JPMS plc's policies for managing conflicts of interest arising as a result of publication and distribution of investment research. Many European regulators require a firm to establish, implement and maintain such a policy. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. Germany: This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch and J.P.Morgan Chase Bank, N.A., Frankfurt Branch which are regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. Hong Kong: The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider/market maker for derivative warrants, callable bull bear contracts and stock options listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk. Japan: There is a risk that a loss may occur due to a change in the price of the shares in the case of share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, JPMorgan Securities Japan Co., Ltd., will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the commission rate which was individually agreed between JPMorgan Securities Japan Co., Ltd., and the customer in advance. Financial Instruments Firms: JPMorgan Securities Japan Co., Ltd., Kanto Local Finance Bureau (kinsho) No. 82 Participating Association / Japan Securities Dealers Association, The Financial Futures Association of Japan, Type II Financial Instruments Firms Association and Japan Investment Advisers Association. Korea: This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Ltd, Seoul Branch. Singapore: JPMSS and/or its affiliates may have a holding in any of the securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Important Disclosures section above. Taiwan: This material is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan Limited). India: For private circulation only, not for sale. Pakistan: For private circulation only, not for sale. New Zealand: This material is issued and distributed by JPMSAL in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. JPMSAL does not issue or distribute this material to members of "the public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMSAL. Canada: The



information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence. **Dubai:** This report has been issued to persons regarded as professional clients as defined under the DFSA rules. **Brazil:** Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com.

General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMS and/or its affiliates and the analyst's involvement with the issuer that is the subject of the research. All pricing is as of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMS distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a J.P. Morgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

"Other Disclosures" last revised November 29, 2014.

Copyright 2015 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.